JP2002512190A5 - - Google Patents

Download PDF

Info

Publication number
JP2002512190A5
JP2002512190A5 JP2000544324A JP2000544324A JP2002512190A5 JP 2002512190 A5 JP2002512190 A5 JP 2002512190A5 JP 2000544324 A JP2000544324 A JP 2000544324A JP 2000544324 A JP2000544324 A JP 2000544324A JP 2002512190 A5 JP2002512190 A5 JP 2002512190A5
Authority
JP
Japan
Prior art keywords
cells
latent
centrifuged
supernatant
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000544324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512190A (ja
JP4607319B2 (ja
Filing date
Publication date
Priority claimed from DE19818044A external-priority patent/DE19818044A1/de
Application filed filed Critical
Publication of JP2002512190A publication Critical patent/JP2002512190A/ja
Publication of JP2002512190A5 publication Critical patent/JP2002512190A5/ja
Application granted granted Critical
Publication of JP4607319B2 publication Critical patent/JP4607319B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000544324A 1998-04-22 1999-04-21 ビタミンpp化合物の使用 Expired - Fee Related JP4607319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19818044A DE19818044A1 (de) 1998-04-22 1998-04-22 Verwendung von Vitamin-PP-Verbindungen
DE19818044.6 1998-04-22
PCT/EP1999/002686 WO1999053920A1 (en) 1998-04-22 1999-04-21 Use of vitamin pp compounds

Publications (3)

Publication Number Publication Date
JP2002512190A JP2002512190A (ja) 2002-04-23
JP2002512190A5 true JP2002512190A5 (enExample) 2010-02-25
JP4607319B2 JP4607319B2 (ja) 2011-01-05

Family

ID=7865483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000544324A Expired - Fee Related JP4607319B2 (ja) 1998-04-22 1999-04-21 ビタミンpp化合物の使用

Country Status (9)

Country Link
US (1) US20100227896A1 (enExample)
EP (1) EP1079832B1 (enExample)
JP (1) JP4607319B2 (enExample)
AT (1) ATE311186T1 (enExample)
AU (1) AU3928299A (enExample)
DE (2) DE19818044A1 (enExample)
DK (1) DK1079832T3 (enExample)
ES (1) ES2253890T3 (enExample)
WO (1) WO1999053920A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
GB0104240D0 (en) * 2001-02-21 2001-04-11 Clariant Int Ltd Copolymer composition having pigment like properties
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
EP2197443A4 (en) * 2007-09-26 2014-01-01 Gemin X Pharmaceuticals Canada Inc COMPOSITIONS AND METHOD FOR LEADING NAD + MIRRORS USING A NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE HEMMER
EP2213288A1 (en) * 2009-01-30 2010-08-04 Karl Welte NAMPT and vitamin B3 for treating or preventing diseases
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
HK1215579A1 (zh) 2012-11-29 2016-09-02 Karyopharm Therapeutics, Inc. 被取代的2,3-二氫苯並呋喃基化合物和其用途
US9856241B2 (en) 2013-07-03 2018-01-02 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
MX2018001979A (es) 2015-08-18 2019-04-25 Karyopharm Therapeutics Inc (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
US11584766B2 (en) 2018-02-05 2023-02-21 The Trustees Of Indiana University Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same
CN115177594B (zh) * 2022-07-04 2023-08-15 武汉大学中南医院 一种阿昔替尼药物制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3148115A (en) * 1958-12-08 1964-09-08 Horner Frank W Ltd Potentiation of tumor-growth inhibition from deoxypyridoxine, testosterone, or 6-mercaptopurine, by 6-aminonicotinamide
JPH04103538A (ja) * 1990-08-24 1992-04-06 Ajinomoto Co Inc 制癌剤副作用抑制剤
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
EP0771204A4 (en) * 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
JPH0881371A (ja) * 1994-09-09 1996-03-26 Suntory Ltd 造血機能亢進剤
AU704723B2 (en) * 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
JP2860637B2 (ja) * 1995-12-11 1999-02-24 末綱 陽子 新規なペプチドおよび活性化酸素阻害剤
JP3836203B2 (ja) * 1995-12-20 2006-10-25 日本臓器製薬株式会社 活性酸素・フリーラジカル消去剤
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624704A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
DE19624668A1 (de) * 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
JPH1045594A (ja) * 1996-07-30 1998-02-17 Mitsubishi Gas Chem Co Inc 活性酸素消去剤

Similar Documents

Publication Publication Date Title
JP2002512190A5 (enExample)
Shimizu et al. Electrically communicating three‐dimensional cardiac tissue mimic fabricated by layered cultured cardiomyocyte sheets
DE3271581D1 (en) Cell-seeding procedures involving fibrous lattices
EP2274419B1 (en) Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations
JP2005527482A5 (enExample)
WO2002072762A3 (en) Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
JP2004502401A (ja) 哺乳動物細胞の展開及びティシュエンジニアリングのための成長因子及びホルモンの使用
BR8602659A (pt) Superficie protetica implantavel para implante em um paciente humano e processo para tratar um implante destinado a implante em um paciente humano
DE69028524D1 (de) In vivo-neomorphogenese von knorpel aus zellkulturen
US20100028308A1 (en) Methods to maintain, improve and restore the cartilage phenotype of chondrocytes
JP2002525043A5 (enExample)
CA2410944A1 (en) Cartilage replacement and method for its production
CN105238738A (zh) 一种仔猪心肌成纤维细胞的分离培养方法
O'Sullivan et al. Adhesion and integration of tissue engineered cartilage to porous polyethylene for composite ear reconstruction
CN101897304A (zh) 一种提高马氏珠母贝插核贝休养期成活率与留核率的养殖方法
CN114618020B (zh) 一种组织工程骨及其制备方法
Cushing et al. Serum deprivation improves seeding and repopulation of acellular matrices with valvular interstitial cells
CN114431145B (zh) 一种基于体细胞胚途径的独蒜兰组织快繁方法
Vogel Lysine synthesis and phytogeny of lower fungi: some chytrids versus Hyphochytrium
CN106943630A (zh) 一种体外培育生长出的透明软骨样块状组织及其制备方法和应用
WO2011037416A3 (ko) 세포이식술을 위한 혼합세포복합체인 세포스페로이드의 제조방법 및 이의 이용방법
Yang et al. A novel possible strategy based on self‐assembly approach to achieve complete periodontal regeneration
CN107557328A (zh) 一种用于分离贴壁细胞的消化液及其分离方法
CN117050937A (zh) 东方蝾螈肢端芽基原代细胞提取方法
CN106701667A (zh) 一种软骨细胞的分离培养方法